Kenya Medical Research Institute
Also known as: Centre for Clinical Research, Kenya Medical Research Institute | Centre for Microbiology Research, Kenya Medical Research Institute | Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya | Centre for Respiratory Disease Research at KEMRI | KEMRI Centre for Clinical Research | KEMRI CGMR-C | KEMRI Wellcome Trust Research Program, Kenya | KEMRI Wellcome Trust Research Programme | KEMRI-Wellcome Trust Research Programme and Imperial College London | KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya. | Kemri - Wellcome Trust Research Programme, Nairobi, Kenya | Kemri- Wellcome Trust Research Programme, Nairobi, Kenya | Kenya Medical Research Institute | Kenya Medical Research Institute, Center for Geographic Medicine Research - Coast | Kenya Medical Research Institute, Centre for Geographic Medicine Research, Coast, kilifi, Kenya | Kenya Medical Research Institute, Centre for Global Health Research, Kisumu, Kenya | Kenya Medical Research Institute (KEMRI) | Kenya Medical Research Institute (KEMRI)/Walter Reed Project (WRP), Kisumu, Kenya | Kenya Medical Research Institute, Kisumu, Kenya | Kenya Medical Research Institute/US Medical Research Directorate-Africa | Kenya Medical Research Institute/Walter Reed Project | Lucas Otieno Tina, MD MSc | Medical Research Institute, Kericho, Kenya | Simon Kariuki
Highest phase reached
Phase 4
First clinical trial
May 1, 1997Last known activity
Nov 30, 2024
Timeline
1970s
- Jan 1, 1979
Kenya Medical Research Institute— Founded
Drugs by trial phase (109 distinct, 89 trials)
Phase 4 (23 own, 0 via acquisition)
Phase 3 (24 own, 0 via acquisition)
- procaine benzylpenicillin
- pancrelipase
- ethambutol
- rifampin
- ivermectin
- ursodeoxycholic acid
- human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant
- miltefosine
- praziquantel
- pyrazinamide
- sodium stibogluconate
- emtricitabine
- human papillomavirus 9-valent vaccine, recombinant
- inactivated influenza vaccine
- zinc dichloride
- +9 more
Phase 2 (37 own, 0 via acquisition)
Phase 1 (11 own, 0 via acquisition)
Indications
Studied for
- Anemia
- Child Nutrition Disorders
- Coinfection
- Communicable Diseases
- Diarrhea
- Dysentery, Bacillary
- Gonorrhea
- Helminthiasis
- HIV Infections
- Infections
- Influenza, Human
- Leishmaniasis
- Leishmaniasis, Visceral
- Malaria
- Malaria, Falciparum
- Malnutrition
- Nematode Infections
- Nutrition Disorders
- Opportunistic Infections
- Papillomavirus Infections
- Parasitemia
- Pneumonia
- Pneumonia, Pneumococcal
- Scabies
- Severe Acute Malnutrition
- Sexually Transmitted Diseases
- Syphilis
- Tinea Capitis
- Tuberculosis
- Tuberculosis, Pulmonary
Recent trials (50)
- NCT06523231CollaboratorPhase 2Nov 30, 2024
- NCT06519994CollaboratorPhase 2Jul 4, 2024
- NCT06087913CollaboratorPhase 1Nov 8, 2023
- NCT06087913Study chairPhase 1Nov 8, 2023
- NCT05934318CollaboratorN/ASep 30, 2023
- NCT05351606CollaboratorPhase 4May 1, 2023
- NCT05914363CollaboratorN/AApr 12, 2023
- NCT05914363OfficialN/AApr 12, 2023
- NCT05549726CollaboratorPhase 4Nov 1, 2022
- NCT05400655CollaboratorPhase 2Sep 14, 2022
- NCT05472311CollaboratorN/AMay 17, 2022
- NCT05140954CollaboratorPhase 2/Phase 3Mar 31, 2022
- NCT05124691CollaboratorPhase 2/Phase 3Jan 17, 2022
- NCT05057858CollaboratorPhase 2/Phase 3Dec 31, 2021
- NCT05175014CollaboratorPhase 4Dec 30, 2021
Details
- Founded
- Nairobi, KE Jan 1, 1979
- Last known activity
- Nov 30, 2024